IMMUNOGENICITY OF TRANSGENIC PLANT-DERIVED HEPATITIS-B SURFACE-ANTIGEN

被引：235

作者：

THANAVALA, Y ^{[1
]}

YANG, YF ^{[1
]}

LYONS, P ^{[1
]}

MASON, HS ^{[1
]}

ARNTZEN, C ^{[1
]}

机构：

[1] TEXAS A&M UNIV,ALKEK INST BIOSCI & TECHNOL,HOUSTON,TX 77030

来源：

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 1995年 / 92卷 / 08期

关键词：

PLANT-DERIVED ANTIGENS; ANTIBODY PRODUCTION; T-CELL PROLIFERATION;

D O I：

10.1073/pnas.92.8.3358

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The focus of the Children's Vaccine Initiative is to encourage the discovery of technology that will make vaccines more readily available to developing countries. Our strategy has been to genetically engineer plants so that they can be used as inexpensive alternatives to fermentation systems for production of subunit antigens. In this paper we report on the immunological response elicited in vivo by using recombinant hepatitis B surface antigen (rHBsAg) purified from transgenic tobacco leaves, The anti-hepatitis B response to the tobacco derived rHBsAg was qualitatively similar to that obtained by immunizing mice with yeast-derived rHBsAg (commercial vaccine). Additionally, T cells obtained from mice primed with the tobacco-derived rHBsAg could be stimulated in vitro by the tobacco-derived rHBsAg, yeast-derived rHBsAg, and by a synthetic peptide that represents part of the alpha determinant located in the S region (139-147) of HBsAg. Further support for the integrity of the T cell epitope of the tobacco-derived rHBsAg was obtained by testing the ability of the primed T Cells to proliferate in vitro after stimulation with a monoclonal anti-idiotype and an anti-idiotype-derived peptide, both of which mimic the group-specific a determinant of HBsAg. In total, we have conclusively demonstrated that both B- and T-cell epitopes of HBsAg are preserved when the antigen is expressed in a transgenic plant.

引用

页码：3358 / 3361

页数：4

共 11 条

[1] Purcell R.H., Proc. Natl. Acad. Sci. USA, 91, pp. 2401-2406, (1994)
[2] Emini E.A., Ellis R.W., Miller W.J., McAleer W.J., Scolnick E.M., Gerety R.J., J. Infect., 13, SUPPL. A, pp. 3-9, (1986)
[3] Mason H.S., Lam D.M.-K., Arntzen C.J., Proc. Natl. Acad. Sci. USA, 89, pp. 11745-11749, (1992)
[4] Pride M.W., Thakur A., Thanavala Y., J. Exp. Med., 177, pp. 127-134, (1993)
[5] Thanavala Y.T., Bond A., Tedder R., Hay F.C., Roitt I.M., Immunology, 55, pp. 197-204, (1985)
[6] Pride M.W., Shi H., Anchin J.M., Linthicum D.C., LoVerde P.T., Thakur A., Thanavala Y., Proc. Natl. Acad. Sci. USA, 89, pp. 11900-11904, (1992)
[7] Alter M.J., Hodler S.C., Margolis H.S., Alexander W.J., Hu P.Y., Judson F.N., Mares A., Miller J.K., Moyer L.A., J. Am. Med. Assoc., 263, pp. 1218-1222, (1990)
[8] Mitchell V.S., Philipose N.M., Sanford J.P., The Children's Vaccine Initiative
[9] Achieving the Vision, (1993)
[10] Arntzen C.J., Mason H.S., Shi J., Haq T.A., Estes M.K., Clements J.D., Vaccines '94: Modern Approaches to New Vaccines Including Prevention of AIDS, pp. 339-348, (1994)

← 1 2 →